GPC3 and/or TGFβ targeting CAR-T cells
ZZCART-003
Phase 1 mab active
Quick answer
GPC3 and/or TGFβ targeting CAR-T cells for Hepatocellular Carcinoma is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Hepatocellular Carcinoma
- Phase
- Phase 1
- Modality
- mab
- Status
- active